HLB Therapeutics Co.,Ltd. (115450.KQ)
- Previous Close
7,790.00 - Open
7,890.00 - Bid 7,820.00 x --
- Ask 7,830.00 x --
- Day's Range
7,720.00 - 7,900.00 - 52 Week Range
4,780.95 - 13,619.05 - Volume
234,813 - Avg. Volume
735,434 - Market Cap (intraday)
654.891B - Beta (5Y Monthly) -0.35
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date May 14, 2025 - May 19, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
HLB Therapeutics Co.,Ltd., a biotech company, develops pharmaceutical products in South Korea and internationally. It is developing GBT-201 using Thymosin beta for the treatment of ophthalmic diseases, such as dry eye syndrome and neurotrophic keratopathy; and OKN-007 for the treatment of glioblastoma brain tumor. It is also involved in the wholesale of vaccines, as well as manufactures electrical and electronic components, such as motors, pumps, and transformers. The company was formerly known as G-treeBNT Co., Ltd. and changed its name to HLB Therapeutics Co.,Ltd. in December 2021. HLB Therapeutics Co.,Ltd. was founded in 2000 and is headquartered in Seongnam, South Korea.
hlbtherapeutics.co.krRecent News: 115450.KQ
View MorePerformance Overview: 115450.KQ
Trailing total returns as of 4/23/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 115450.KQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 115450.KQ
View MoreValuation Measures
Market Cap
652.38B
Enterprise Value
637.96B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
11.43
Price/Book (mrq)
4.14
Enterprise Value/Revenue
11.61
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-41.49%
Return on Assets (ttm)
-2.27%
Return on Equity (ttm)
-12.97%
Revenue (ttm)
54.93B
Net Income Avi to Common (ttm)
-22.26B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
37.77B
Total Debt/Equity (mrq)
12.84%
Levered Free Cash Flow (ttm)
-9.51B